Suresh S. Ramalingam

103.8k total citations · 15 hit papers
593 papers, 25.5k citations indexed

About

Suresh S. Ramalingam is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Suresh S. Ramalingam has authored 593 papers receiving a total of 25.5k indexed citations (citations by other indexed papers that have themselves been cited), including 406 papers in Oncology, 372 papers in Pulmonary and Respiratory Medicine and 177 papers in Molecular Biology. Recurrent topics in Suresh S. Ramalingam's work include Lung Cancer Treatments and Mutations (332 papers), Lung Cancer Research Studies (161 papers) and Lung Cancer Diagnosis and Treatment (105 papers). Suresh S. Ramalingam is often cited by papers focused on Lung Cancer Treatments and Mutations (332 papers), Lung Cancer Research Studies (161 papers) and Lung Cancer Diagnosis and Treatment (105 papers). Suresh S. Ramalingam collaborates with scholars based in United States, United Kingdom and South Korea. Suresh S. Ramalingam's co-authors include Taofeek K. Owonikoko, Chandra P. Belani, Fadlo R. Khuri, Myung‐Ju Ahn, Rathi N. Pillai, Serban Ghiorghiu, Pasi A. Jänne, Helen Mann, Tony Mok and James Chih‐Hsin Yang and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Suresh S. Ramalingam

566 papers receiving 25.2k citations

Hit Papers

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive... 2011 2026 2016 2021 2016 2015 2017 2013 2017 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
    2016 2.4k citations Myung‐Ju Ahn, Suresh S. Ramalingam et al. profile →
  2. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
    2015 1.6k citations Suresh S. Ramalingam, Myung‐Ju Ahn et al. profile →
  3. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
    2017 724 citations Alice O. Kamphorst, Andreas Wieland et al. Science profile →
  4. Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions
    2013 617 citations Suresh S. Ramalingam, Paul W. Doetsch et al. profile →
  5. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
    2017 582 citations Alice O. Kamphorst, Rathi N. Pillai et al. profile →
  6. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
    2018 511 citations Suresh S. Ramalingam et al. Journal of Clinical Oncology profile →
  7. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
    2018 446 citations Alice O. Kamphorst, Rathi N. Pillai et al. profile →
  8. Lung cancer: New biological insights and recent therapeutic advances
    2011 391 citations Suresh S. Ramalingam, Taofeek K. Owonikoko et al. profile →
  9. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
    2017 380 citations Suresh S. Ramalingam et al. Journal of Clinical Oncology profile →
  10. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
    2018 342 citations Suresh S. Ramalingam, Martin Reck et al. Journal of Clinical Oncology profile →
  11. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
    2020 303 citations Suresh S. Ramalingam, Myung‐Ju Ahn et al. profile →
  12. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
    2018 269 citations Suresh S. Ramalingam et al. profile →
  13. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
    2021 196 citations Suresh S. Ramalingam et al. profile →
  14. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
    2023 130 citations Suresh S. Ramalingam et al. profile →
  15. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
    2023 95 citations Myung‐Ju Ahn, Suresh S. Ramalingam et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suresh S. Ramalingam United States 74 15.5k 14.5k 8.8k 4.2k 2.6k 593 25.5k
Luis Paz‐Ares Spain 73 13.2k 0.9× 11.4k 0.8× 7.6k 0.9× 4.2k 1.0× 2.2k 0.8× 690 23.0k
Kenneth J. O’Byrne Australia 72 12.7k 0.8× 10.5k 0.7× 8.4k 1.0× 5.0k 1.2× 2.2k 0.8× 598 23.7k
Enriqueta Felip Spain 75 23.6k 1.5× 22.9k 1.6× 9.0k 1.0× 5.7k 1.4× 2.8k 1.0× 796 33.7k
Kazuhiko Nakagawa Japan 80 22.1k 1.4× 20.8k 1.4× 9.9k 1.1× 4.4k 1.1× 1.5k 0.6× 815 32.3k
D. Ross Camidge United States 77 15.0k 1.0× 16.9k 1.2× 8.6k 1.0× 4.6k 1.1× 1.1k 0.4× 539 24.2k
Federico Cappuzzo Italy 63 16.9k 1.1× 16.9k 1.2× 7.0k 0.8× 4.3k 1.0× 1.6k 0.6× 360 24.6k
Keunchil Park South Korea 75 17.9k 1.2× 17.0k 1.2× 6.2k 0.7× 4.0k 1.0× 2.3k 0.9× 567 27.4k
Fabrice Barlési France 65 15.4k 1.0× 13.4k 0.9× 5.1k 0.6× 3.3k 0.8× 2.7k 1.0× 570 22.1k
Giampaolo Tortora Italy 69 13.8k 0.9× 7.8k 0.5× 9.9k 1.1× 4.8k 1.1× 1.9k 0.7× 639 24.4k
Rafael Rosell Spain 72 15.2k 1.0× 16.6k 1.1× 10.0k 1.1× 6.0k 1.4× 1.3k 0.5× 546 26.8k

Countries citing papers authored by Suresh S. Ramalingam

Since Specialization
Citations

This map shows the geographic impact of Suresh S. Ramalingam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suresh S. Ramalingam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suresh S. Ramalingam more than expected).

Fields of papers citing papers by Suresh S. Ramalingam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suresh S. Ramalingam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suresh S. Ramalingam. The network helps show where Suresh S. Ramalingam may publish in the future.

Co-authorship network of co-authors of Suresh S. Ramalingam

This figure shows the co-authorship network connecting the top 25 collaborators of Suresh S. Ramalingam. A scholar is included among the top collaborators of Suresh S. Ramalingam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suresh S. Ramalingam. Suresh S. Ramalingam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Itzstein, Mitchell S. von, Suzanne E. Dahlberg, David E. Gerber, et al.. (2025). Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer. The Oncologist. 30(3). 1 indexed citations
2.
Reuss, Joshua E., Nishant Gandhi, Phillip Walker, et al.. (2025). Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking. Lung Cancer. 200. 108101–108101. 1 indexed citations
3.
Ramalingam, Suresh S., et al.. (2025). Drought’s physiological footprint: implications for crop improvement in rice. Molecular Biology Reports. 52(1). 298–298. 1 indexed citations
4.
Zerdan, Maroun Bou, Badi El Osta, Ticiana Leal, et al.. (2025). Survival Determinants and Sociodemographic Disparities in Early-Onset Non–Small Cell Lung Cancer. JAMA Network Open. 8(10). e2537307–e2537307.
5.
Hummel, Horst-Dieter, Myung‐Ju Ahn, Fiona Blackhall, et al.. (2025). Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial. Advances in Therapy. 42(4). 1950–1964. 1 indexed citations
6.
Koo, Junghui, Chang-Soo Seong, Rebecca E. Parker, et al.. (2024). Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1 -Mutant Lung Cancer. Cancer Research. 84(22). 3761–3771. 3 indexed citations
7.
Ramalingam, Suresh S., et al.. (2024). Elucidation of nutritional properties and cooking quality traits of under-exploited pigmented rice (Oryza sativa L.) landraces. Indian Journal of Genetics and Plant Breeding (The). 84(2). 292–294.
8.
Zhu, Lei, Zhen Chen, Hongjing Zang, et al.. (2021). Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. Cancer Research. 81(18). 4822–4834. 50 indexed citations
9.
Qian, Guoqing, Jianping Guo, C. Hu, et al.. (2021). Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Molecular Cancer Research. 19(10). 1622–1634. 34 indexed citations
10.
Shin, Dong M., Sreenivas Nannapaneni, Mihir R. Patel, et al.. (2020). Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. Clinical Cancer Research. 26(22). 5860–5868. 13 indexed citations
11.
Shi, Puyu, You-Take Oh, Liang Deng, et al.. (2017). Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. Clinical Cancer Research. 23(21). 6567–6579. 113 indexed citations
12.
Kamphorst, Alice O., Andreas Wieland, Tahseen H. Nasti, et al.. (2017). Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent. Science. 355(6332). 1423–1427. 724 indexed citations breakdown →
13.
Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2016). Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(8). 1937–1944. 65 indexed citations
14.
Kang, Hyunseok, Suresh S. Ramalingam, Madhusmita Behera, et al.. (2014). Class I HDACs Are Mediators of Smoke Carcinogen–Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer. Cancer Prevention Research. 7(3). 351–361. 32 indexed citations
15.
Xie, Maohua, Yun Yen, Taofeek K. Owonikoko, et al.. (2013). Bcl2 Induces DNA Replication Stress by Inhibiting Ribonucleotide Reductase. Cancer Research. 74(1). 212–223. 39 indexed citations
16.
Li, Rui, Zhongliang Hu, Shi‐Yong Sun, et al.. (2013). Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 12(10). 2200–2212. 129 indexed citations
17.
Pillai, Rathi N., Gabriel Sica, Shaojin You, et al.. (2013). CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC. Clinical Cancer Research. 19(6). 1603–1611. 22 indexed citations
18.
Park, Dongkyoo, Andrew T. Magis, Rui Li, et al.. (2013). Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer. Cancer Research. 73(17). 5485–5496. 59 indexed citations
19.
Yue, Ping, et al.. (2011). Retinoic Acid Enhances TRAIL-Induced Apoptosis in Cancer Cells by Upregulating TRAIL Receptor 1 Expression. Cancer Research. 71(15). 5245–5254. 42 indexed citations
20.
Ramalingam, Suresh S., Suzanne E. Dahlberg, Corey J. Langer, et al.. (2007). Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. Journal of Clinical Oncology. 26(1). 60–65. 251 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luis Paz‐Ares Breakdown of academic impact, for papers by Kenneth J. O’Byrne Breakdown of academic impact, for papers by Enriqueta Felip Breakdown of academic impact, for papers by Kazuhiko Nakagawa Breakdown of academic impact, for papers by D. Ross Camidge Breakdown of academic impact, for papers by Federico Cappuzzo Breakdown of academic impact, for papers by Keunchil Park Breakdown of academic impact, for papers by Fabrice Barlési Breakdown of academic impact, for papers by Giampaolo Tortora Breakdown of academic impact, for papers by Rafael Rosell
Rankless by CCL
2026